Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice

Stephen A. Morris, Louis M. Weiss, Stephen Factor, John P. Bilezikian, Herbert Tanowitz, Murray Wittner

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The influence of long-term verapamil administration on the consequences of Trypanosoma crud infection in mice was studied with regard to animal mortality, morbidity, myocardial pathologic features and myocardial beta-adrenergic adenylate cyclase activity. Verapamil administration dramatically decreased the mortality rate from 60% to 6% during the 70 day period of infection. Three clinical stages of infection were evident. In the acute stage (17 days after infection with maximal parasitemia), verapamil treatment not only decreased the incidence of myocardial disease (fibrosis and inflammation), but also protected myocardial beta-adrenergic adenylate cyclase activity. In addition, there was no increase in total body weight, which was regarded as an index of right-sided heart failure. In the subacute stage (30 to 60 days after infection), administration of verapamil continued to decrease myocardial disease and preserve beta-adrenergic adenylate cyclase activity. In addition, verapamil ameliorated the morbidity and mortality associated with this stage of infection. The chronic stage of infection was characterized by a decrease in myocardial disease and in beta-adrenergic adenylate cyclase activity. Thus, independent of the state of infection, long-term verapamil treatment enhanced betaadrenergic adenylate cyclase activity. In addition, verapamil ameliorated the morbidity associated with infection. Although the relation among these various effects of verapamil in the setting of T. cruzi infection remains to be determined, collectively the results suggested that verapamil administration attenuated the consequences of T. cruzi infection.

Original languageEnglish (US)
Pages (from-to)782-789
Number of pages8
JournalJournal of the American College of Cardiology
Volume14
Issue number3
DOIs
StatePublished - 1989

Fingerprint

Verapamil
Cardiomyopathies
Infection
Adenylyl Cyclases
Adrenergic Agents
Morbidity
Mortality
Trypanosoma
Parasitemia
Fibrosis
Heart Failure
Body Weight
Inflammation

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice. / Morris, Stephen A.; Weiss, Louis M.; Factor, Stephen; Bilezikian, John P.; Tanowitz, Herbert; Wittner, Murray.

In: Journal of the American College of Cardiology, Vol. 14, No. 3, 1989, p. 782-789.

Research output: Contribution to journalArticle

Morris, Stephen A. ; Weiss, Louis M. ; Factor, Stephen ; Bilezikian, John P. ; Tanowitz, Herbert ; Wittner, Murray. / Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice. In: Journal of the American College of Cardiology. 1989 ; Vol. 14, No. 3. pp. 782-789.
@article{89c7c5d7bcb04ce6b6851a68ffb0f5a8,
title = "Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice",
abstract = "The influence of long-term verapamil administration on the consequences of Trypanosoma crud infection in mice was studied with regard to animal mortality, morbidity, myocardial pathologic features and myocardial beta-adrenergic adenylate cyclase activity. Verapamil administration dramatically decreased the mortality rate from 60{\%} to 6{\%} during the 70 day period of infection. Three clinical stages of infection were evident. In the acute stage (17 days after infection with maximal parasitemia), verapamil treatment not only decreased the incidence of myocardial disease (fibrosis and inflammation), but also protected myocardial beta-adrenergic adenylate cyclase activity. In addition, there was no increase in total body weight, which was regarded as an index of right-sided heart failure. In the subacute stage (30 to 60 days after infection), administration of verapamil continued to decrease myocardial disease and preserve beta-adrenergic adenylate cyclase activity. In addition, verapamil ameliorated the morbidity and mortality associated with this stage of infection. The chronic stage of infection was characterized by a decrease in myocardial disease and in beta-adrenergic adenylate cyclase activity. Thus, independent of the state of infection, long-term verapamil treatment enhanced betaadrenergic adenylate cyclase activity. In addition, verapamil ameliorated the morbidity associated with infection. Although the relation among these various effects of verapamil in the setting of T. cruzi infection remains to be determined, collectively the results suggested that verapamil administration attenuated the consequences of T. cruzi infection.",
author = "Morris, {Stephen A.} and Weiss, {Louis M.} and Stephen Factor and Bilezikian, {John P.} and Herbert Tanowitz and Murray Wittner",
year = "1989",
doi = "10.1016/0735-1097(89)90126-5",
language = "English (US)",
volume = "14",
pages = "782--789",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice

AU - Morris, Stephen A.

AU - Weiss, Louis M.

AU - Factor, Stephen

AU - Bilezikian, John P.

AU - Tanowitz, Herbert

AU - Wittner, Murray

PY - 1989

Y1 - 1989

N2 - The influence of long-term verapamil administration on the consequences of Trypanosoma crud infection in mice was studied with regard to animal mortality, morbidity, myocardial pathologic features and myocardial beta-adrenergic adenylate cyclase activity. Verapamil administration dramatically decreased the mortality rate from 60% to 6% during the 70 day period of infection. Three clinical stages of infection were evident. In the acute stage (17 days after infection with maximal parasitemia), verapamil treatment not only decreased the incidence of myocardial disease (fibrosis and inflammation), but also protected myocardial beta-adrenergic adenylate cyclase activity. In addition, there was no increase in total body weight, which was regarded as an index of right-sided heart failure. In the subacute stage (30 to 60 days after infection), administration of verapamil continued to decrease myocardial disease and preserve beta-adrenergic adenylate cyclase activity. In addition, verapamil ameliorated the morbidity and mortality associated with this stage of infection. The chronic stage of infection was characterized by a decrease in myocardial disease and in beta-adrenergic adenylate cyclase activity. Thus, independent of the state of infection, long-term verapamil treatment enhanced betaadrenergic adenylate cyclase activity. In addition, verapamil ameliorated the morbidity associated with infection. Although the relation among these various effects of verapamil in the setting of T. cruzi infection remains to be determined, collectively the results suggested that verapamil administration attenuated the consequences of T. cruzi infection.

AB - The influence of long-term verapamil administration on the consequences of Trypanosoma crud infection in mice was studied with regard to animal mortality, morbidity, myocardial pathologic features and myocardial beta-adrenergic adenylate cyclase activity. Verapamil administration dramatically decreased the mortality rate from 60% to 6% during the 70 day period of infection. Three clinical stages of infection were evident. In the acute stage (17 days after infection with maximal parasitemia), verapamil treatment not only decreased the incidence of myocardial disease (fibrosis and inflammation), but also protected myocardial beta-adrenergic adenylate cyclase activity. In addition, there was no increase in total body weight, which was regarded as an index of right-sided heart failure. In the subacute stage (30 to 60 days after infection), administration of verapamil continued to decrease myocardial disease and preserve beta-adrenergic adenylate cyclase activity. In addition, verapamil ameliorated the morbidity and mortality associated with this stage of infection. The chronic stage of infection was characterized by a decrease in myocardial disease and in beta-adrenergic adenylate cyclase activity. Thus, independent of the state of infection, long-term verapamil treatment enhanced betaadrenergic adenylate cyclase activity. In addition, verapamil ameliorated the morbidity associated with infection. Although the relation among these various effects of verapamil in the setting of T. cruzi infection remains to be determined, collectively the results suggested that verapamil administration attenuated the consequences of T. cruzi infection.

UR - http://www.scopus.com/inward/record.url?scp=0024460544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024460544&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(89)90126-5

DO - 10.1016/0735-1097(89)90126-5

M3 - Article

VL - 14

SP - 782

EP - 789

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 3

ER -